Presentation of Complete Response of Stage IV Pancreatic Cancer by Kleef R et al.


At the conference, CICON 2019 - TRANSLATING SCIENCE INTO SURVIVAL from September 25.-28., 2019 in Paris, Ralf Kleef et al. from Vienna presented a case report on "Complete response of stage IV pancreatic cancer combining dose adapted checkpoint inhibitors with interleukin-2 (IL-2) and fever range hyperthermia". This presentation follows several presentations at international academic conferences, listed in the Selected publications and Running clinical trials auf - look at Oncology / 6. Congress abstracts.

Systematic pre-clinical research has revealed the powerful effects of fever-range hyperthermia on anti-cancer immune functions - reviewed in Repasky EA, Evans SS, Dewhirst M (2013): Temperature Matters! And Why it Should Matter to Tumor Immunologists.

It is evident that fever-range hyperthermia cannot act as a monotherapy in cancer therapy, but can probably significantly increase the effects of other immunotherapies. The new approach of a multi-modular therapy, including dose-reduced checkpoint inhibitors and fever-range whole-body hyperthermia, might be one example where one of the most ancient immune stimulating therapies could find its place in modern cancer therapy.


Print Email

heckel medizintechnik GmbH

Olgastrasse 25
73728 Esslingen

Tel: ++49 (0)711 - 128989 - 0
Fax: ++49 (0)711 - 128989 - 20


Visit us on Facebook

Visit us on Linkedin





We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.